Investment analysts at Truist Financial started coverage on shares of Phreesia (NYSE:PHR – Get Free Report) in a note issued to investors on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Truist Financial’s target price suggests a potential upside of 44.51% from the stock’s current price.
Several other research analysts have also recently weighed in on the stock. DA Davidson upgraded shares of Phreesia from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $30.00 to $32.00 in a research report on Wednesday, January 17th. Raymond James cut their price target on shares of Phreesia from $30.00 to $25.00 and set an “outperform” rating for the company in a research note on Thursday, December 7th. KeyCorp lowered their price objective on shares of Phreesia from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Thursday, December 7th. JMP Securities dropped their price objective on shares of Phreesia from $39.00 to $28.00 and set a “market outperform” rating for the company in a report on Wednesday, December 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Thursday, January 18th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.79.
View Our Latest Research Report on PHR
Phreesia Stock Performance
NYSE PHR opened at $24.22 on Monday. The company’s 50 day simple moving average is $24.78 and its two-hundred day simple moving average is $21.32. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.02 and a quick ratio of 2.02. Phreesia has a 1 year low of $12.05 and a 1 year high of $38.86. The stock has a market capitalization of $1.35 billion, a PE ratio of -9.04 and a beta of 0.95.
Phreesia (NYSE:PHR – Get Free Report) last posted its earnings results on Wednesday, December 6th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.10. The business had revenue of $91.62 million during the quarter, compared to analysts’ expectations of $89.60 million. Phreesia had a negative return on equity of 54.28% and a negative net margin of 42.70%. The firm’s revenue was up 25.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.76) earnings per share. Analysts predict that Phreesia will post -2.32 earnings per share for the current fiscal year.
Insider Activity at Phreesia
In other Phreesia news, General Counsel Allison C. Hoffman sold 1,316 shares of Phreesia stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $24.55, for a total value of $32,307.80. Following the transaction, the general counsel now directly owns 144,464 shares of the company’s stock, valued at approximately $3,546,591.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Phreesia news, General Counsel Allison C. Hoffman sold 1,316 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $24.55, for a total transaction of $32,307.80. Following the completion of the sale, the general counsel now owns 144,464 shares of the company’s stock, valued at approximately $3,546,591.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Chaim Indig sold 3,586 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $24.55, for a total transaction of $88,036.30. Following the completion of the transaction, the chief executive officer now owns 1,280,410 shares in the company, valued at approximately $31,434,065.50. The disclosure for this sale can be found here. Insiders sold 10,184 shares of company stock worth $251,630 in the last ninety days. 5.80% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC increased its stake in shares of Phreesia by 1,987.3% during the fourth quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock valued at $34,000 after buying an additional 1,411 shares during the period. Captrust Financial Advisors boosted its holdings in Phreesia by 154.6% in the second quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock valued at $36,000 after acquiring an additional 866 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Phreesia during the 1st quarter valued at $43,000. State of Wyoming raised its holdings in Phreesia by 34.6% in the 2nd quarter. State of Wyoming now owns 1,918 shares of the company’s stock worth $59,000 after purchasing an additional 493 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Phreesia by 85.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,137 shares of the company’s stock worth $80,000 after purchasing an additional 1,445 shares in the last quarter. Institutional investors own 94.37% of the company’s stock.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Phreesia, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Phreesia wasn’t on the list.
While Phreesia currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Source: marketbeat.com
